 |
 |
 |
 |
 |
 |
 |
| (a) |
Operating income in Fiscal 2008 included purchased in-process research and development expenses of $10.0 million and $7.5 million recorded in connection with the EvamistTM and GestivaTM acquisitions, respectively (see Note 3 of the Notes to the Consolidated Financial Statements). The impact of these items was to decrease net income on an after-tax basis by $11.7 million in fiscal 2008.
|
|
|
|
| (b) |
Operating income in fiscal 2006 included an expense of $30.4 million recognized in connection with the FemmePharma acquisition that consisted of $29.6 million for acquired in-process research and development and $0.9 million for direct expenses related to the transaction (see Note 3 to the Notes to Consolidated Financial Statements). The impact of this item, which is not deductible for tax purposes, was to decrease net income by $30.4 million in fiscal 2006.
|
|
|